Please use this identifier to cite or link to this item:
|Title:||Impact of botanical fermented foods on metabolic biomarkers and gut microbiota in adults with metabolic syndrome and type 2 diabetes: a systematic review protocol.||Austin Authors:||Chan, Miin;Baxter, Helen ;Larsen, Nadja;Jespersen, Lene;Ekinci, Elif I ;Howell, Kate||Affiliation:||Department of Medicine, Austin Health and University of Melbourne, Heidelberg, Victoria, Australia
School of Agriculture and Food, University of Melbourne, Melbourne, Victoria, Australia
Austin Health Sciences Library, Austin Health, Heidelberg, Victoria, Australia
Department of Food Science, University of Copenhagen, Frederiksberg, Denmark..
|Issue Date:||30-Jul-2019||metadata.dc.date:||2019-07-30||Publication information:||BMJ Open 2019; 9(7): e029242||Abstract:||Dysfunctional gut microbiota is a common finding in patients with metabolic syndrome (MetS) and type 2 diabetes mellitus (T2DM). Recent clinical trials have assessed whether botanical fermented foods (BFFs) have beneficial effects on metabolic biomarkers, inflammatory markers and gut microbiota. The aim of this review is to critically evaluate all randomised controlled trials (RCTs) of BFF for evidence of impact on the outcome measures of these disease states. Four electronic databases (Embase, MEDLINE, CENTRAL and Google Scholar) as well as the grey literature will be searched from inception to present without language or publication status restrictions applied. Eligible RCTs which have enrolled adult participants with T2DM, any MetS components or combinations of these components, treated prophylactically or therapeutically with any botanical fermented food intervention, compared with a control group (no intervention, placebo or active control) will be assessed. Primary outcomes are related to the target conditions, including metabolic biomarkers, inflammatory markers and gut microbiota composition/function. Using Covidence, two independent investigators will conduct title and abstract screening, followed by full-text screening to identify appropriate studies. Methodological quality of the trials will be assessed using the Cochrane risk of bias assessment tool. Findings will be summarised with a narrative synthesis of the differences between included studies. A meta-analysis will be conducted if sufficient data are obtained. Ethical approval is not required as primary data will not be collected. Results will be disseminated through peer-reviewed publication, conference presentations and press. CRD42018117766.||URI:||http://ahro.austin.org.au/austinjspui/handle/1/21471||DOI:||10.1136/bmjopen-2019-029242||ORCID:||0000-0001-6579-8584
|PubMed URL:||31366656||Type:||Journal Article||Subjects:||cardiovascular disease
type 2 diabetes
|Appears in Collections:||Journal articles|
Show full item record
checked on Apr 16, 2021
Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.